{"created":"2023-06-20T15:46:17.992828+00:00","id":800,"links":{},"metadata":{"_buckets":{"deposit":"547eb23a-3e8e-42c7-a0df-c93c77b1b244"},"_deposit":{"created_by":4,"id":"800","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"800"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00000800","sets":["2:15:17"]},"author_link":["2712"],"item_5_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"薬物血中濃度モニタリングにより至適トラフ濃度の観点から確立したテイコプラニンの推奨初期ローディングドーズと治療効果","subitem_alternative_title_language":"ja"}]},"item_5_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"189","bibliographicPageStart":"185","bibliographicVolumeNumber":"12","bibliographic_titles":[{"bibliographic_title":"Journal of Infection and Chemotherapy","bibliographic_titleLang":"en"}]}]},"item_5_date_granted_17":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2008-10-17"}]},"item_5_degree_grantor_15":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"浜松医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"13802","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_5_degree_name_12":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_5_description_10":{"attribute_name":"注記","attribute_value_mlt":[{"subitem_description":"浜松医科大学学位論文 医博論第458号(平成20年10月17日）","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_5_description_13":{"attribute_name":"学位の区分","attribute_value_mlt":[{"subitem_description":"doctoral","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_5_description_14":{"attribute_name":"学位の分野","attribute_value_mlt":[{"subitem_description":"医学系研究科","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_5_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Teicoplanin has a long serum half-life, and therefore it takes time to reach a steady-state concentration.  An initial loading procedure has been recommended for teicoplanin to enable prompt reaching of  the optimal serum trough level (10-15μg/ml).  However, the dose of teicoplanin that should be administered to patients with varying renal function levels remains inconclusive.  In this study, we monitored the serum concentrations of teicoplanin in the patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and compared different teicoplanin serum concentrations and their clinical efficacy, investigating the significance of the mean dose administered during the initial 3 days.   The study included 48 patients with MRSA pneumonia.  The peak and trough concentrations of teicoplanin were determined utilizing a fluorescence polarization immunoassay and a two-compartment Bayesian population model.   Teicoplanin was given at a loading dose of 400 or 800 mg on the first day, followed by maintenance doses of 200 or 400 mg.  The mean initial dose (MID) over the first 3 days was calculated as (loading dose + dose for 2nd day + dose for 3rd day) / 3.  Patients with MID of 266.7 mg or less (400mg for loading, 200mg over the 2nd and 3rd day) did not have a trough level that exceeded 10μg/ml at the point before the injection on the 4th day.  Even in patients with hemodialysis (HD), an MID of 266.7 mg was not enough to provide a trough level of 10μg/ml.  Patients with an MID than 533.3mg had significantly elevated trough levels, showing better outcomes.  A multiple regression formula for predicting trough level before the fourth day of administration is given as: 0.034 + 0.030 x (MID, mg) - 0.057 x creatinine clearance (Ccr; ml/min).   These findings suggest that 800 mg as an initial dose, followed by 400 mg maintenance doses over the following 2 days, makes it possible to safely attain an optimal trough level, even in the patients with HD.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_dissertation_number_18":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第458号"}]},"item_5_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer","subitem_publisher_language":"en"}]},"item_5_relation_26":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"16944256","subitem_relation_type_select":"PMID"}}]},"item_5_relation_28":{"attribute_name":"出版社DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s10156-006-0446-y","subitem_relation_type_select":"DOI"}}]},"item_5_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2006","subitem_rights_language":"en"}]},"item_5_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1341-321X","subitem_source_identifier_type":"PISSN"}]},"item_5_source_id_20":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1437-7780","subitem_source_identifier_type":"EISSN"}]},"item_5_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Sato, Masaki","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"DT_ron458ronbun.pdf","filesize":[{"value":"200.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"論文本文","objectType":"fulltext","url":"https://hama-med.repo.nii.ac.jp/record/800/files/DT_ron458ronbun.pdf"},"version_id":"a0b167e0-3ee0-450d-9eeb-8a67d0a117f6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Therapeutic drug monitoring","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Teicoplanin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Loading dose","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"MRSA","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level","subitem_title_language":"en"}]},"item_type_id":"5","owner":"4","path":["17"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"800","relation_version_is_last":true,"title":["Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-10-30T04:20:04.104036+00:00"}